Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Horgusluoglu-Moloch E, Arnold M, Kaddurah-Daouk RF, Zhang B
After a year of treatment, people who received lixisenatide showed better outcomes in their movement symptoms compared to those who received a placebo
Advise the patient to read the FDA-approved patient labeling (Patient Information)
This is why choosing a reputable supplier is critical
www.nature.com , Torekov, S
## Availability Status: March 2026 - **FDA status:** Phase 3 clinical trials ongoing - **Expected approval timeline:** Potentially 2026-2027 - **Brand availability:** None yet - **Current access:** Compounding pharmacies (503A/503B) with valid prescription For a detailed breakdown of [retatrutide's FDA approval status and projected timeline](/guides/retatrutide-fda-approval-2026-timeline-status), see our dedicated tracker the date brand pricing becomes available depends directly on when retatrutide clears FDA review
US$ 28.22
US$ 28.05
US$ 25.77
US$ 28.96
US$ 25.80
